These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23385800)

  • 1. Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease.
    Robbie SJ; Lundh von Leithner P; Ju M; Lange CA; King AG; Adamson P; Lee D; Sychterz C; Coffey P; Ng YS; Bainbridge JW; Shima DT
    Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1490-500. PubMed ID: 23385800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
    Yafai Y; Yang XM; Niemeyer M; Nishiwaki A; Lange J; Wiedemann P; King AG; Yasukawa T; Eichler W
    Eur J Pharmacol; 2011 Sep; 666(1-3):12-8. PubMed ID: 21620822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.
    Kumar R; Knick VB; Rudolph SK; Johnson JH; Crosby RM; Crouthamel MC; Hopper TM; Miller CG; Harrington LE; Onori JA; Mullin RJ; Gilmer TM; Truesdale AT; Epperly AH; Boloor A; Stafford JA; Luttrell DK; Cheung M
    Mol Cancer Ther; 2007 Jul; 6(7):2012-21. PubMed ID: 17620431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit.
    Iwase T; Oveson BC; Hashida N; Lima e Silva R; Shen J; Krauss AH; Gale DC; Adamson P; Campochiaro PA
    Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):503-11. PubMed ID: 23169884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing bortezomib for choroidal neovascularization treatment via antagonizing VEGF-A and PDGF-D mediated signaling.
    Liu Y; Feng M; Cai J; Li S; Dai X; Shan G; Wu S
    Exp Eye Res; 2021 Mar; 204():108446. PubMed ID: 33476605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib.
    Takahashi K; Saishin Y; Saishin Y; King AG; Levin R; Campochiaro PA
    Arch Ophthalmol; 2009 Apr; 127(4):494-9. PubMed ID: 19365030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys.
    Horita S; Watanabe M; Katagiri M; Nakamura H; Haniuda H; Nakazato T; Kagawa Y
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00545. PubMed ID: 31763044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice.
    Kang S; Roh YJ; Kim IB
    Exp Eye Res; 2013 Jul; 112():125-33. PubMed ID: 23701975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockage of PI3K/mTOR Pathways Inhibits Laser-Induced Choroidal Neovascularization and Improves Outcomes Relative to VEGF-A Suppression Alone.
    Ma J; Sun Y; López FJ; Adamson P; Kurali E; Lashkari K
    Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3138-44. PubMed ID: 27304845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
    Kim YH; Kim MJ; Choe SW; Sprecher D; Lee YJ; P Oh S
    J Thromb Haemost; 2017 Jun; 15(6):1095-1102. PubMed ID: 28339142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
    Kim KL; Suh W
    Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic effects of axitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on laser-induced choroidal neovascularization in mice.
    Kang S; Roh CR; Cho WK; Park KC; Yang KJ; Choi HS; Kim SH; Roh YJ
    Curr Eye Res; 2013 Jan; 38(1):119-27. PubMed ID: 23013553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Efficacy of an Injectable Microsphere-Hydrogel Ocular Drug Delivery System.
    Osswald CR; Guthrie MJ; Avila A; Valio JA; Mieler WF; Kang-Mieler JJ
    Curr Eye Res; 2017 Sep; 42(9):1293-1301. PubMed ID: 28557571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes.
    Gross N; Ranjbar M; Evers C; Hua J; Martin G; Schulze B; Michaelis U; Hansen LL; Agostini HT
    Mol Vis; 2013; 19():54-61. PubMed ID: 23335851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor.
    Kinose F; Roscilli G; Lamartina S; Anderson KD; Bonelli F; Spence SG; Ciliberto G; Vogt TF; Holder DJ; Toniatti C; Thut CJ
    Mol Vis; 2005 May; 11():366-73. PubMed ID: 15951738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF is major stimulator in model of choroidal neovascularization.
    Kwak N; Okamoto N; Wood JM; Campochiaro PA
    Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3158-64. PubMed ID: 10967078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides.
    de Cogan F; Hill LJ; Lynch A; Morgan-Warren PJ; Lechner J; Berwick MR; Peacock AFA; Chen M; Scott RAH; Xu H; Logan A
    Invest Ophthalmol Vis Sci; 2017 May; 58(5):2578-2590. PubMed ID: 28494491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical application of recombinant calreticulin peptide, vasostatin 48, alleviates laser-induced choroidal neovascularization in rats.
    Bee YS; Sheu SJ; Ma YL; Lin HC; Weng WT; Kuo HM; Hsu HC; Tang CH; Liou JC; Tai MH
    Mol Vis; 2010 Apr; 16():756-67. PubMed ID: 20454694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema.
    Doukas J; Mahesh S; Umeda N; Kachi S; Akiyama H; Yokoi K; Cao J; Chen Z; Dellamary L; Tam B; Racanelli-Layton A; Hood J; Martin M; Noronha G; Soll R; Campochiaro PA
    J Cell Physiol; 2008 Jul; 216(1):29-37. PubMed ID: 18330892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.
    Verheijen RB; Beijnen JH; Schellens JHM; Huitema ADR; Steeghs N
    Clin Pharmacokinet; 2017 Sep; 56(9):987-997. PubMed ID: 28185218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.